Posted in News
ATMP: A new Tag has been created for ATMP (advanced therapeutic medicinal products) to enable Trusts to start to monitor their use of these products. Currently, the product included in the Tag are autologous human corneal epithelial cells, axicabtagene cilocleucel, characterised autologous human cartilage cells, darvadstocel, generic spherox (Spheroids of human autologous matrix-associated chondrocytes) and talimogene laherparepvec.
Tisangelecleucel and Zynteglo (genetically modified autologous CD34+ cell enriched population that contains haematopoietic stem cells (HSC) transduced with lentiviral vector (LVV) encoding the βA-T87Q-globin gene) will be added when they are available on dm+d.
An additional product, Voretigene neparvovec (Luxturna) is approved by NICE but is neither included on the dm+d nor are there any unmapped records in the data.
One common factor for each of these personalised treatments is that they are not ‘off the shelf’ pharmacy products. While the Tag will enable Trusts to track use through pharmacy, if these products are being sourced through other Departments within the Trust it will not be possible to map this use to dm+d from the current data sources.